Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)

We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(®) is a registered trade name of Eli Lilly and Company) Observat...

Descripción completa

Detalles Bibliográficos
Autores principales: Langdahl, Bente L., Ljunggren, Östen, Benhamou, Claude-Laurent, Marin, Fernando, Kapetanos, George, Kocjan, Tomaz, Lespessailles, Eric, Napoli, Nicola, Nikolic, Tatjana, Petto, Helmut, Moll, Thomas, Lindh, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960288/
https://www.ncbi.nlm.nih.gov/pubmed/27137783
http://dx.doi.org/10.1007/s00223-016-0143-5

Ejemplares similares

Ejemplares similares